Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial.

Refractory prolonged isolated thrombocytopenia (RPIT) is an intractable complication after allogeneic hematopoietic cell transplantation (HCT), which often leads to poor prognosis. A clinical study was designed to validate the efficacy and safety of low-dose decitabine for RPIT after HCT and explore the related underlying mechanisms. Eligible patients were randomly allocated to receive 1 of 3 interventions: arm A, low-dose decitabine (15 mg/m2 daily IV for 3 consecutive days [days 1-3]) plus recombinant human thrombopoietin (300 U/kg daily); arm B, decitabine alone; or arm C, conventional treatment. The primary end point was the response rate of platelet recovery at day 28 after treatment. Secondary end points included megakaryocyte count 28 days after treatment and survival during additional follow-up of 24 weeks. Among the 91 evaluable patients, response rates were 66.7%, 73.3%, and 19.4% for the 3 arms, respectively (P < .001). One-year survival rates in arms A (64.4% ± 9.1%) and B (73.4% ± 8.8%) were similar (P = .662), and both were superior to that in arm C (41.0% ± 9.8%; P = .025). Megakaryocytes, endothelial cells (ECs), and cytokines relating to megakaryocyte migration and EC damage were improved in patients responding to decitabine. This study showed low-dose decitabine improved platelet recovery as well as overall survival in RPIT patients after transplantation. This trial was registered at www.clinicaltrials.gov as #NCT02487563.

[1]  朱利安·保罗·汉史克,et al.  Decitabine , 2009, Reactions Weekly.

[2]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[3]  Xin Wang,et al.  A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia , 2019, American journal of hematology.

[4]  Xiaowen Tang,et al.  Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  S. Davies,et al.  ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy. , 2017, The New England journal of medicine.

[6]  Yu Wang,et al.  Atorvastatin enhances endothelial cell function in posttransplant poor graft function. , 2016, Blood.

[7]  D. Link,et al.  The hematopoietic stem cell niche in homeostasis and disease. , 2015, Blood.

[8]  S. Forman,et al.  Hematopoietic Cell Transplantation , 2015 .

[9]  J. Bussel,et al.  Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial , 2015, The Lancet.

[10]  Depei Wu,et al.  Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study. , 2015, JAMA oncology.

[11]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[12]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. George,et al.  Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim , 2013, European journal of haematology.

[14]  T. Luft,et al.  Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Zongdong Li,et al.  The effect of decitabine on megakaryocyte maturation and platelet release , 2011, Thrombosis and Haemostasis.

[16]  W. Shannon,et al.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.

[17]  F. Appelbaum,et al.  Hematopoietic-cell transplantation at 50. , 2007, The New England journal of medicine.

[18]  R. Hoffman,et al.  Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. , 2007, Cancer research.

[19]  S. Rafii,et al.  Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. , 2006, The Journal of clinical investigation.

[20]  R. Yamazaki,et al.  Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover , 2006, Bone Marrow Transplantation.

[21]  D. Scadden,et al.  The hematopoietic stem cell in its place , 2006, Nature Immunology.

[22]  S. Morrison,et al.  Supplemental Experimental Procedures , 2022 .

[23]  S. Rafii,et al.  Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis , 2004, Nature Medicine.

[24]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[25]  U. V. von Andrian,et al.  Total body irradiation causes profound changes in endothelial traffic molecules for hematopoietic progenitor cell recruitment to bone marrow. , 2002, Blood.

[26]  K. Sullivan,et al.  Secondary failure of platelet recovery after hematopoietic stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[28]  R. Taichman,et al.  Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. , 2000, The Journal of clinical investigation.

[29]  Dan,et al.  Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes , 1998, British journal of haematology.

[30]  Richard J. Jones,et al.  Acute bleeding after bone marrow transplantation (BMT)- incidence and effect on survival. A quantitative analysis in 1,402 patients. , 1998, Blood.

[31]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[32]  H. Nieuwenhuis,et al.  Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation , 1991 .

[33]  J. Lipton,et al.  Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. , 1985, Blood.